What Is
PLUVICTO?
PLUVICTO—now available for PSMA+ mCRPC before chemotherapy
If you’ve had hormone therapy, it may be time for PLUVICTO. Learn more about eligibility by clicking the link below.
PLUVICTO is different
It's not chemotherapy. It's targeted treatment called radioligand therapy (RLT) for PSMA+ mCRPC.
The FIRST and ONLY RLT for PSMA+ mCRPC
RLT is a different type of radiation therapy that is injected or infused and targets a biomarker called PSMA.
Remember it in 3 steps
PLUVICTO is designed to find and attack PSMA+ cells. PSMA is found on many prostate cancer cells and also some healthy cells.
When PLUVICTO finds PSMA on the surface of a cell, it goes into the cell.
Once inside, PLUVICTO releases radiation, damaging or destroying the cell from within. It may also affect some nearby healthy cells.
mCRPC, metastatic castration-resistant prostate cancer; PSMA, prostate-specific membrane antigen; PSMA+, PSMA positive.